MESSAGE
DATE | 2018-02-07 |
FROM | From: "APhA - American Pharmacists Association"
|
SUBJECT | Subject: [Hangout - NYLXS] Immunizing Pharmacists News - February 7, 2018
|
From hangout-bounces-at-nylxs.com Mon Feb 12 11:46:42 2018 Return-Path: X-Original-To: archive-at-mrbrklyn.com Delivered-To: archive-at-mrbrklyn.com Received: from www2.mrbrklyn.com (www2.mrbrklyn.com [96.57.23.82]) by mrbrklyn.com (Postfix) with ESMTP id 8499716113A; Mon, 12 Feb 2018 11:46:41 -0500 (EST) X-Original-To: hangout-at-www2.mrbrklyn.com Delivered-To: hangout-at-www2.mrbrklyn.com Received: by mrbrklyn.com (Postfix, from userid 1000) id 311C7161134; Mon, 12 Feb 2018 11:46:38 -0500 (EST) Resent-From: Ruben Safir Resent-Date: Mon, 12 Feb 2018 11:46:38 -0500 Resent-Message-ID: <20180212164638.GA27088-at-www2.mrbrklyn.com> Resent-To: hangout-at-mrbrklyn.com X-Original-To: ruben-at-mrbrklyn.com Delivered-To: ruben-at-mrbrklyn.com Received: from mail79-176.us1.msgfocus.com (mail79-176.us1.msgfocus.com [81.29.79.176]) by mrbrklyn.com (Postfix) with ESMTP id 55434161132 for ; Wed, 7 Feb 2018 18:36:15 -0500 (EST) DKIM-Signature: v=1; a=rsa-sha1; c=relaxed/relaxed; s=msgf; d=msgfocus.com; h=Subject:X-Mailer:Message-ID:Reply-To:To:List-Unsubscribe:From:Date:MIME-Version:Content-Type; bh=A0uP672XFZfZQwsw9LUpbcPcTGI=; b=tGv2iao15C7JkDIqTnxU6xpkN4dnwMa7GSHLN6Cxa4aii7cL5vbu28lto21oLG2CwBnNDBPWSzyi J01o/kMI4q7PmzCLwYm4UVcnz7HBpqGtft5ULKFuK2iG/QN9wXhPi7ENU7Eyt43q7x/Gmk3zyr+W nuo+x7D7ZFsKiUVI5WQ= DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=aphanet.org; s=hrs-dkim; t=1518046573; bh=U4EmN5Ma3q+hO2Ke/+QAbhZA747V/wYPYuw9aDL1F8k=; h=Subject:X-Mailer:Message-ID:Reply-To:To:List-Unsubscribe:From: Date:MIME-Version:Content-Type; b=plsh2wIwuo0IJkHht9DCLh3k0zJ2fdJ6oWxw7LuNvu1dsgr72p1FigpiCONgwPYF6 AMxpNpsBcQDcCt0ounNjtI52PakIzG1aLIroUM6fJDjCyStXTaQ/EdjxtobVFmYoAj L4LV40FZgdlyjv5FNtgL/6mFNa0qzh9HDf2kxNN8= X-Mailer: MessageFocus v2 launch Message-ID: To: ruben-at-mrbrklyn.com From: "APhA - American Pharmacists Association" Date: Wed, 7 Feb 2018 23:36:13 +0000 MIME-Version: 1.0 Subject: [Hangout - NYLXS] Immunizing Pharmacists News - February 7, 2018 X-BeenThere: hangout-at-nylxs.com X-Mailman-Version: 2.1.17 Precedence: list Reply-To: APhA - American Pharmacists Association List-Id: NYLXS Tech Talk and Politics List-Unsubscribe: , List-Post: List-Help: List-Subscribe: , Content-Type: multipart/mixed; boundary="===============0364574100==" Errors-To: hangout-bounces-at-nylxs.com Sender: "Hangout"
--===============0364574100== Content-Type: multipart/alternative; boundary="--17C5E3F746EDDA92B065881187F6"
----17C5E3F746EDDA92B065881187F6 Content-Type: text/plain; charset="UTF-8" Content-Transfer-Encoding: quoted-printable
If you are having trouble viewing this email, view it online.
Immunizing Pharmacist
News
Widespread Influenza Has Killed 37 Children; CDC Provides Related Media Adv= isory CDC has reported in its Weekly U.S. Influenza Surveillance Report, FluView http://messaging.aphanet.org/c/11tr4hnm9oI29Mi3BPfjx6IMOrF, that as of the = week ending January 20, influenza has caused nearly 12,000 hospitalizations= and 37 pediatric deaths since October 1, 2017. Because it takes time for d= eaths outside of a hospital to be investigated, the reported number of pedi= atric deaths is likely to be an underestimate.
The geographic spread of influenza in Puerto Rico and 49 states was reporte= d as widespread; Guam reported regional activity; the District of Columbia = and one state reported local activity; and the U.S. Virgin Islands reported= sporadic activity.
On January 26, CDC held an update for the media titled "CDC Update on Flu A= ctivity." Part of the introductory statement from Dan Jernigan, MD, MPH, di= rector, Influenza Division, National Center for Immunization and Respirator= y Diseases, CDC, is reprinted below.
It has been a tough flu season so far, this year. And while flu activity is= beginning to go down in parts of the country, it remains high for most the= U.S., with some areas still rising. Most people with influenza are being i= nfected with the H3N2 influenza virus. And in seasons where H3N2 is the mai= n cause of influenza, we see more cases, more visits to the doctor, more ho= spitalizations, and more deaths, especially among older people. This season= now looking like the 2014=E2=80=9315 season where H3N2 predominated. ... W= e=E2=80=99ve experienced two notable characteristics of flu this season: Th= e first is that flu activity became widespread within almost all states and= jurisdictions at the same time. The second is that flu activity has now st= ayed at the same level for 3 weeks in a row, with 49 states reporting wides= pread activity, each week, for 3 weeks. We often see different parts of the= country =E2=80=9Clight up=E2=80=9D at different times, but for the past 3 = weeks, the entire country has been experiencing lots of flu, all at the sam= e time.
Access the complete transcript or audio recording http://messaging.aphanet.org/c/11tr4pa4OdSx7dlBKYNo3vv59mS from this media = advisory.
Influenza vaccination is recommended for everyone six months of age and old= er. If you don't provide influenza vaccination in your clinic, please recom= mend vaccination to your patients and refer them to a clinic or pharmacy th= at provides vaccines or to the HealthMap Vaccine Finder http://messaging.aphanet.org/c/11tr4wWNt3324Ep9U8lszUhnui5 to locate sites = near their workplaces or homes that offer influenza vaccination services.
Following is a list of resources related to influenza disease and vaccinati= on for healthcare professionals and the public:
CDC's Seasonal Flu web section http://messaging.aphanet.org/c/11tr4MweMHo1ZwwgcrrBCHPYa8v CDC's FluView web section http://messaging.aphanet.org/c/11tr4UiXrwywWXzOlAZG96Cgv3I CDC's Free Resources related to influenza http://messaging.aphanet.org/c/11tr525G6lJ1UoDmuKxKFvoyPYV IAC's handouts related to influenza http://messaging.aphanet.org/c/11tr59SoLaTwRPGUDU5PbUaRaU8 HealthMap Vaccine Finder http://messaging.aphanet.org/c/11tr5hF7q041PgKsN3DTIiX9vPl National Adult and Influenza Immunization Summit http://messaging.aphanet.org/c/11tr5prQ4PewMHO0WdbYeHJrQKy website The Summit Buzz http://messaging.aphanet.org/c/11tr5xeyJEp1K8Rz5mK2L6vKbFL Newsletter of th= e National Adult and Influenza Immunization Summit Influenza Vaccine Availability Tracking System=E2=80=94IVATS http://messaging.aphanet.org/c/11tr5F1hotzwHzV7ewi7hvi2wAY a resource for h= ealthcare settings looking to purchase influenza vaccine
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January= 31, 2018.
CDC Publishes ACIP Recommendations for Use of Herpes Zoster Vaccines in MMWR CDC published Recommendations of the Advisory Committee on Immunization Pra= ctices for Use of Herpes Zoster Vaccines http://messaging.aphanet.org/c/11tr5MO03iK1F0YFnFQbNU4kRwb in the January 2= 6 issue of MMWR (pages 103=E2=80=938). The "Introduction" and "Clinical Gui= dance" sections are reprinted below:
Introduction On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, Glax= oSmithKline), a 2-dose, subunit vaccine containing recombinant glycoprotein= E in combination with a novel adjuvant (AS01B), was approved by the Food a= nd Drug Administration for the prevention of herpes zoster in adults aged = =E2=89=A550 years. The vaccine consists of 2 doses (0.5 mL each), administe= red intramuscularly, 2=E2=80=936 months apart. On October 25, 2017, the Adv= isory Committee on Immunization Practices (ACIP) recommended the recombinan= t zoster vaccine (RZV) for use in immunocompetent adults aged =E2=89=A550 y= ears.
Herpes zoster is a localized, usually painful, cutaneous eruption resulting= from reactivation of latent varicella zoster virus (VZV). Herpes zoster is= common: approximately one million cases occur each year in the United Stat= es. The incidence increases with age, from five cases per 1,000 population = in adults aged 50=E2=80=9359 years to 11 cases per 1,000 population in pers= ons aged =E2=89=A580 years. Postherpetic neuralgia, commonly defined as per= sistent pain for at least 90 days following the resolution of the herpes zo= ster rash, is the most common complication and occurs in 10%=E2=80=9313% of= herpes zoster cases in persons aged >50 years. Among persons with herpes z= oster, the risk for developing postherpetic neuralgia also increases with a= ge.
Zoster Vaccine Live (ZVL) (Zostavax, Merck and Co., Inc.), a 1-dose live at= tenuated strain of VZV, is licensed for the prevention of herpes zoster in = immunocompetent adults aged =E2=89=A550 years and is recommended by the ACI= P for use in immunocompetent adults aged =E2=89=A560 years. Since licensure= , vaccine coverage has increased each year, and by 2016, 33% of adults aged= =E2=89=A560 years reported receipt of the vaccine (CDC, provisional unpubl= ished data). ACIP considered use of RZV, as well as existing recommendation= s, to develop vaccination policy which would be safe and reduce disease bur= den. This report serves as a supplement to the 2008 Prevention of Herpes Zo= ster Recommendations of ACIP for the use of ZVL in adults aged =E2=89=A560 = years and subsequent updates; it outlines recent ACIP recommendations as we= ll as guidance for use of RZV and ZVL in adults.
Clinical Guidance General use. RZV may be used in adults aged =E2=89=A550 years, irrespective= of prior receipt of varicella vaccine or ZVL, and does not require screeni= ng for a history of chickenpox (varicella). ZVL remains a recommended vacci= ne for prevention of herpes zoster in immunocompetent adults aged =E2=89=A5= 60 years. Care should be taken not to confuse ZVL, which is stored in the f= reezer and administered subcutaneously, with RZV, which is stored in the re= frigerator and administered intramuscularly.
Dosing schedule. Following the first dose of RZV, the second dose should be= given 2=E2=80=936 months later. The vaccine series need not be restarted i= f more than 6 months have elapsed since the first dose; however, the effica= cy of alternative dosing regimens has not been evaluated, data regarding th= e safety of alternative regimens are limited, and individuals might remain = at risk for herpes zoster during a longer than recommended interval between= doses 1 and 2. If the second dose of RZV is given less than 4 weeks after = the first, the second dose should be repeated. Two doses of the vaccine are= necessary regardless of prior history of herpes zoster or prior receipt of= ZVL.
Timing of RZV for persons previously vaccinated with ZVL. Age and time sinc= e receipt of ZVL may be considered to determine when to vaccinate with RZV.= Studies examined the safety and immunogenicity of RZV vaccination administ= ered =E2=89=A55 years after ZVL; shorter intervals have not been studied. H= owever, there are no data or theoretical concerns to indicate that RZV woul= d be less safe or less effective when administered at an interval of <5 yea= rs. Clinical trials indicated lower efficacy of ZVL in adults aged =E2=89= =A570 years; therefore, a shorter interval may be considered based on the r= ecipient=E2=80=99s age when ZVL was administered. Based on expert opinion, = RZV should not be given <2 months after receipt of ZVL.
Coadministration with other vaccines. CDC=E2=80=99s general best practice g= uidelines for immunization advise that recombinant and adjuvanted vaccines,= such as RZV, can be administered concomitantly, at different anatomic site= s, with other adult vaccines. Concomitant administration of RZV with Fluari= x Quadrivalent (influenza vaccine) (QIV) has been studied, and there was no= evidence for interference in the immune response to either vaccine or safe= ty concerns. Evaluation of coadministration of RZV with 23-valent pneumococ= cal polysaccharide vaccine (PPSV23, Pneumovax23) and tetanus toxoid, reduce= d diphtheria toxoid, and acellular pertussis vaccine, adsorbed (Tdap, Boost= rix) is ongoing. The safety and efficacy of administration of two adjuvante= d vaccines (e.g., RZV and adjuvanted influenza vaccine [Fluad]), either con= comitantly or at other intervals, have not been evaluated.
Counseling for reactogenicity. Before vaccination, providers should counsel= RZV recipients about expected systemic and local reactogenicity. Reactions= to the first dose did not strongly predict reactions to the second dose; v= accine recipients should be encouraged to complete the series even if they = experienced a grade 1=E2=80=933 reaction to the first dose of RZV. The impa= ct of prophylactic analgesics in conjunction with RZV has not been studied.
Access the complete recommendation: Recommendations of the Advisory Committ= ee on Immunization Practices for Use of Herpes Zoster Vaccines http://messaging.aphanet.org/c/11tr5UAII7UwCs2dwPogkiQDcro.
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January= 31, 2018.
Draft Agenda for February ACIP Meeting Available http://messaging.aphanet.org/c/11tr6aaa1Mfwxk9jP8upn6pdShO ACIP will hold its next meeting on February 21=E2=80=9322 in Atlanta. The d= raft agenda is now available online. To attend the meeting, ACIP attendees = (participants and visitors) must register online. The registration deadline= for non-U.S. citizens is January 24; for U.S. citizens, it's February 5. R= egistration is not required to watch the meeting via webcast or listen to t= he proceedings via phone. See the first link below for the toll-free phone = number and passcode.
Related Links
ACIP Meeting Information http://messaging.aphanet.org/c/11tr6hWSGBq1uLcRYi2tTvbwdd1 web page February meeting registration information http://messaging.aphanet.org/c/11tr6pJBlqAwscgq7rAypTXOy8e
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January= 24, 2018.
Large Review Study Investigates the Effectiveness of Patient Reminders Rega= rding Vaccination On January 18, the Cochrane Database of Systemic Reviews published a large = review and meta-analysis by Vann Jacobson et al. titled Patient reminder an= d recall interventions to improve immunization rates. http://messaging.aphanet.org/c/11tr6xwk0fL1pDjYgB8CWiK6T3r "Background" and= "Conclusions" sections of the abstract are reprinted below:
Background Immunization rates for children and adults are rising, but coverage levels = have not reached optimal goals. As a result, vaccine-preventable diseases s= till occur. In an era of increasing complexity of immunization schedules, r= ising expectations about the performance of primary care, and large demands= on primary care providers, it is important to understand and promote inter= ventions that work in primary care settings to increase immunization covera= ge. One common theme across immunization programs in many nations involves = the challenge of implementing a population-based approach and identifying a= ll eligible recipients, for example the children who should receive the mea= sles vaccine. However, this issue is gradually being addressed through the = availability of immunization registries and electronic health records. A se= cond common theme is identifying the best strategies to promote high vaccin= ation rates. Three types of strategies have been studied: (1) patient-orien= ted interventions, such as patient reminder or recall, (2) provider interve= ntions, and (3) system interventions, such as school laws. One of the most = prominent intervention strategies, and perhaps best studied, involves patie= nt reminder or recall systems. This is an update of a previously published = review.
Authors' Conclusions Patient reminder and recall systems, in primary care settings, are likely t= o be effective at improving the proportion of the target population who rec= eive immunizations.
Access Patient reminder and recall interventions to improve immunization ra= tes http://messaging.aphanet.org/c/11tr6Fj2F4Vwn4nwpKGHsHwpdYE.
Related Link
MedPage Today: Patient Reminders Effective at Improving Receipt of Vaccines= =E2=80=94Text messages, postcards, and autodialer calls worked best http://messaging.aphanet.org/c/11tr6N5LjU61kvr4yUeLZ6iHyTR
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January= 31, 2018.
Southeast Michigan Hepatitis A Outbreak Continues to Rise; Now With 677 Cas= es and 22 Deaths Southeast Michigan=E2=80=99s hepatitis A outbreak, which has continued to r= ise, now has 677 cases and 22 deaths across 15 counties, according to the M= ichigan Department of Health and Human Services. The outbreak, which began = in August 2016, has appeared to spread through person-to-person contact and= drug use. The national shortage of the hepatitis A vaccine has led to prio= ritizing vaccination efforts to reach the people who are the most at risk a= nd the areas with the most cases. Outside of Michigan, San Diego has been t= he hardest hit by a hepatitis A outbreak, with almost 600 cases and 20 deat= hs since August 2016.
Related Links
Michigan Department of Health and Human Services: Hepatitis A Southeast Mic= higan Outbreak http://messaging.aphanet.org/c/11tr6UStYJgwhWuCI3MQvv4ZTP4 (1/17) CNN: Michigan hit hard by deadly hepatitis A outbreak http://messaging.aphanet.org/c/11tr72FcDyr1fnyaRdkV1TRieKh (1/16) San Diego County Health and Human Services Agency: San Diego Hepatitis A Ou= tbreak http://messaging.aphanet.org/c/11tr7arVinBwcOBJ0mSZyiDAzFu (1/16)
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January= 24, 2018.
Study Found More Than One Third of People Infected With HIV in U.S. Had Mis= sed Opportunities to Initiate Hepatitis B Vaccination On December 26, the Annals of Internal Medicine published an article online= by John Weiser et al. titled Low Prevalence of Hepatitis B Vaccination Amo= ng Patients Receiving Medical Care for HIV Infection in the United States, = 2009 to 2012 http://messaging.aphanet.org/c/11tr7ieDXcM1afFh9wr44HpSUAH. Three sections = of the abstract are reprinted below:
Background Persons with HIV infection are at increased risk for hepatitis B virus infe= ction. In 2016, the World Health Organization resolved to eliminate hepatit= is B as a public health threat by 2030.
Objective To estimate the prevalence of hepatitis B vaccination among U.S. patients r= eceiving medical care for HIV infection (=E2=80=9CHIV patients=E2=80=9D).
Conclusion More than one third of U.S. HIV patients had missed opportunities to initia= te hepatitis B vaccination. Meeting goals for hepatitis B elimination will = require increased vaccination of HIV patients in all practice settings, par= ticularly at facilities not funded by RWHAP.
Access the abstract: Low Prevalence of Hepatitis B Vaccination Among Patien= ts Receiving Medical Care for HIV Infection in the United States, 2009 to 2= 012 http://messaging.aphanet.org/c/11tr7xO5gR7157MnrPxd7uYtAr7.
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January= 31, 2018.
Canadian Study Finds Significant Association Between Influenza and Acute My= ocardial Infarction On January 25, the New England Journal of Medicine published an article onl= ine by Jeffrey Kwong et al. titled Acute Myocardial Infarction after Labora= tory-Confirmed Influenza Infection http://messaging.aphanet.org/c/11tr7FANVGhw2yPVAZ5hDTKLVmk. The "Background= " and "Conclusions" sections of the abstract are reprinted below:
Background Acute myocardial infarction can be triggered by acute respiratory infection= s. Previous studies have suggested an association between influenza and acu= te myocardial infarction, but those studies used nonspecific measures of in= fluenza infection or study designs that were susceptible to bias. We evalua= ted the association between laboratory-confirmed influenza infection and ac= ute myocardial infarction.
Conclusions We found a significant association between respiratory infections, especial= ly influenza, and acute myocardial infarction. (Funded by the Canadian Inst= itutes of Health Research and others.)
Access the abstract: Acute Myocardial Infarction after Laboratory-Confirmed= Influenza Infection http://messaging.aphanet.org/c/11tr7NnwAvs0ZZTtK8Dmaix4ghx.
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January= 31, 2018.
Deadline Extended to February 8=E2=80=A6Nominations Open for the National A= dult and Influenza Immunization Summit Excellence Awards The National Adult and Influenza Immunization Summit (NAIIS) is soliciting = candidates for the 2018 NAIIS Immunization Excellence Awards. The 2018 awar= ds recognize individuals and organizations that have made extraordinary con= tributions towards improving vaccination rates within their communities dur= ing 2017. The awards focus on individuals and organizations that exemplify = the meaning of the "immunization neighborhood" (collaboration, coordination= , and communication among immunization stakeholders dedicated to meeting th= e immunization needs of the patient and protecting the community from vacci= ne-preventable diseases). Unless an award criteria is specifically focused = on influenza, it is the intent of the Summit to recognize broader adult imm= unization activities.
A national winner will be selected for each award category, and, where appr= opriate, an honorable mention recipient. The winners will be presented with= their awards at the National Adult and Influenza Immunization Summit meeti= ng to be held in May 17=E2=80=9318 in Atlanta. The national winner in each = category will be invited to present their programs at the National Adult an= d Influenza Immunization Summit meeting.
Access information on the award categories and the nomination form http://messaging.aphanet.org/c/11tr7VaffkCvXqX1TibqGHjmBcK.
Related Links
NAIIS website http://messaging.aphanet.org/c/11tr82WXU9N0US0A2rJvd65EW7X NAIIS newsletter: The Summit Buzz http://messaging.aphanet.org/c/11tr8aJGyYXvSj48bBhzJuRXh3a
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January= 31, 2018.
WHO Report on Immunization in Older Adults Worldwide Published in Vaccine On January 12, Report on WHO meeting on immunization in older adults: Genev= a, Switzerland, 22=E2=80=9323 March 2017 http://messaging.aphanet.org/c/11tr8iwpdO80PK7GkKPEfTEfBYn, was published o= nline in Vaccine.
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January= 31, 2018.
CDC Publishes Report About People Who Erroneously Received an Excess Dosage= of Yellow Fever Vaccine CDC published Notes from the Field : Errors in Administration of an Excess = Dosage of Yellow Fever Vaccine=E2=80=94United States, 2017 http://messaging.aphanet.org/c/11tr8qj7SDivNbbetUnIMiqxWTA in the January 2= 6 issue of MMWR (pages 109=E2=80=9310).
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January= 31, 2018.
WHO Publishes Report from the December Meeting of the Global Advisory Commi= ttee on Vaccine Safety in Weekly Epidemiological Record WHO published a report from the meeting of the Global Advisory Committee on= Vaccine Safety, held on December 6=E2=80=937, 2017, in the January 19 issu= e of its Weekly Epidemiological Record. The report is titled Global Advisor= y Committee on Vaccine Safety, 6=E2=80=937 December 2017. http://messaging.aphanet.org/c/11tr8y5Qxst0KCeMD3VNiHcQhON
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January= 24, 2018.
Back to top
Resources
IAC's Recently Updated Clinic Tools: Screening for Vaccine Contraindication= s and Precautions Web Page Provides Resources From IAC and CDC to Help You = Assess Whether Your Patients Can Be Vaccinated Recently updated, IAC's Clinic Tools: Screening for Vaccine Contraindicatio= ns and Precautions http://messaging.aphanet.org/c/11tr8FSzchDvI3ikMdtRP5Z8CK0 web page on immu= nize.org is a collection of resources from IAC and CDC related to vaccine c= ontraindications and precautions. This web page can be found by selecting t= he "Clinic Tools" tab (third from the left) in the light gray banner across= the top of every immunize.org web page and then selecting "Screening for C= ontraindications" in the drop-down menu.
In the left-hand column of the page you will find IAC's educational materia= ls related to vaccine administration. From here, you can access IAC's scree= ning checklists for vaccination as well as links to other related resources= available on immunize.org. The right-hand column of the page includes reso= urces from CDC.
Visit the Clinic Tools: Screening for Vaccine Contraindications and Precaut= ions http://messaging.aphanet.org/c/11trpvb5qSkqawY8yR7DQEmLQo6 on immunize.org.
Related Links
Clinic Tools http://messaging.aphanet.org/c/11trpCXO5HuV7Y1GI0FIn394bjj web section on i= mmunize.org http://messaging.aphanet.org/c/11trpKKwKwFq5p5eRadMTrVmwew Clinic Tools: Administering Vaccines http://messaging.aphanet.org/c/11trpSxfplPV2Q8N0jLRpQHER9J web page Clinic Tools: Vaccine Storage and Handling http://messaging.aphanet.org/c/11trq0jY4b0q0hcl9tjVWftXc4W web page
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January= 31, 2018.
IAC Updates "Administering Vaccines: Dose, Route, Site, and Needle Size=E2= =80=9D IAC recently revised Administering Vaccines: Dose, Route, Site, and Needle = Size http://messaging.aphanet.org/c/11trq86GJ0aUXIfTiCS0sEgfx09 to incorporate t= he recently licensed recombinant zoster vaccine (RZV), Shingrix, that is ad= ministered intramuscularly, as well as the recently licensed hepatitis B va= ccine (Heplisav-B) that is licensed for use in adults.
Related Links
IAC's educational materials on vaccine administration http://messaging.aphanet.org/c/11trqfTpnPlpV9jrrMq4Z32xRVm IAC's Clinic Tools: Administering Vaccines http://messaging.aphanet.org/c/11trqnG82EvUSAmZAVY9vrOQcQz page CDC's Vaccine Administration http://messaging.aphanet.org/c/11trqvsQHtGpQ1qxK5we1QB8xLM web section CDC's Vaccine Administration e-Learn http://messaging.aphanet.org/c/11trqDfzmiQUNsu5Tf4iyfnqSGZ CDC's Resource Library http://messaging.aphanet.org/c/11trqSP0FXbUIkBcbyarB2W1yxp with 18 brief st= and-alone videos on vaccine administration
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January= 31, 2018.
IAC Updates "How to Administer Intramuscular and Subcutaneous Vaccine Injec= tions" and "How to Administer Intramuscular and Subcutaneous Vaccine Inject= ions to Adults" IAC recently updated How to Administer Intramuscular and Subcutaneous Vacci= ne Injections http://messaging.aphanet.org/c/11trr0BJkMmpFLEKkHIw7rIjTsC and How to Admin= ister Intramuscular and Subcutaneous Vaccine Injections to Adults http://messaging.aphanet.org/c/11trr8orZBwUDcIitRgADQuCenP. Changes were ma= de to incorporate the recently licensed recombinant zoster vaccine (RZV), S= hingrix, that is administered intramuscularly, in contrast to the live zost= er vaccine (LZV), Zostavax, which is administered subcutaneously.
Related Links
IAC's educational materials on vaccine administration http://messaging.aphanet.org/c/11trrgbaEqHpADLQD0OFafgUzj2 IAC's Clinic Tools: Administering Vaccines http://messaging.aphanet.org/c/11trrnXTjfRUy4PoMamJGE3cUef page CDC's Vaccine Administration http://messaging.aphanet.org/c/11trrvKBY52pvvSWVjUOd2Pvf9s web section CDC's Vaccine Administration e-Learn http://messaging.aphanet.org/c/11trrDxkCUcUsWWv4tsSJrBNA4F CDC's Resource Library http://messaging.aphanet.org/c/11trrLk3hJnpqo03dD0XfQo5UZS with 18 brief st= and-alone videos on vaccine administration
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January= 31, 2018.
Vaccine Education Center Updates Multiple Resources, Including Its Mumps Q&= A Sheet and Adult Vaccination Booklet The Vaccine Education Center http://messaging.aphanet.org/c/11trrT6LWyxUnP3BmMz1MfaofV5 at Children's Ho= spital of Philadelphia has updated the following three print resources:
"Mumps: What you need to know" addresses mumps disease and vaccination. Thi= s Q&A sheet now also covers recent college outbreaks and the new ACIP third= dose recommendation. This piece is part of VEC's Vaccine- and Vaccine Safe= ty-Related Q&A Sheets series http://messaging.aphanet.org/c/11trs0TuBnIplg79vW76iDWGAQi, and is availabl= e in English http://messaging.aphanet.org/c/11trsgsVV23pg8efOfdflrvhgGI and Spanish http://messaging.aphanet.org/c/11trsofEzRdUdzhNXoLjRQhzBBV. =E2=80=9CPrescription for Information=E2=80=9D pads (in English http://messaging.aphanet.org/c/11trsw2neGopb0lm6yjoof3RWx8 and Spanish http://messaging.aphanet.org/c/11trsDP5TvyU8roUfHRsUDQahsl) have been updat= ed to include all recently revised Q&A sheets. Individual sheets can be sen= t home with patients/parents so they can view the materials online at their= convenience. The "Adults and Vaccines: A Lifetime of Health" booklet was updated to incl= ude information about the new shingles vaccine. Other minor changes were al= so made, including updated statistics, information about egg allergies, and= mentions of recent measles and mumps outbreaks. This booklet is also avail= able in English http://messaging.aphanet.org/c/11trsLBOykJp5SssoRpxr2CsCny and Spanish http://messaging.aphanet.org/c/11trsToxd9TU3jw0y0XBXroKXiL.
You can download all VEC resources for free or order print copies from VEC http://messaging.aphanet.org/c/11trt1bfRZ4p0KzyHavGtQb3idY (some free; most= for a nominal charge).
In addition, Do I Need to Avoid Being Around Infants After a Shingles Vacci= ne? http://messaging.aphanet.org/c/11trt8XYwOeTYbD6Qk3L0eXlD9b from the video s= eries Talking about Vaccines with Dr. Paul Offit http://messaging.aphanet.org/c/11trtgKHbDpoVCGEZtBPwDJDY4o has been updated= to address the new shingles vaccine, Shingrix.
Related Link
Vaccine Education Center at Children's Hospital of Philadelphia http://messaging.aphanet.org/c/11trtoxpQszTT3Kd8D9U32vWiZB website
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January= 31, 2018.
Vaccine Education Center Publishes January Issue of Its Newsletter for Heal= th Care Professionals The Vaccine Education Center (VEC) http://messaging.aphanet.org/c/11trtE6Ra6UTNVRjqWg35Q4wYQ1 at Children's Ho= spital of Philadelphia publishes a monthly immunization-focused newsletter = titled Vaccine Update for Healthcare Professionals http://messaging.aphanet.org/c/11trtLTzOW5oLmURA5O7CeQPjLe. The January iss= ue includes the following articles:
Chasing Seasonal Influenza=E2=80=94The Need for a Universal Influenza Vacci= ne http://messaging.aphanet.org/c/11trtTGitLfTINYpJfmc8DD7EGr by Paul A. Offit= , MD CDC Issues New Requirements for VFC Vaccine Storage http://messaging.aphanet.org/c/11tru1t18AqoGf1XSoUgF2ppZBE by IAC executive= director Deborah L. Wexler, MD Updated ACIP Recommendations Related to Mumps and Hepatitis B http://messaging.aphanet.org/c/11tru9fJNpATDG5w1yslbrbIkwR by Charlotte A. = Moser and Paul A. Offit, MD
Additional articles and resources, including handouts for patients, are ava= ilable in the full newsletter http://messaging.aphanet.org/c/11truh2sseLoB794aI0pHPY0Fs4.
Access the sign-up form http://messaging.aphanet.org/c/11truoPb73VTyycCjRyueeKj0nh to subscribe to = Vaccine Update for Healthcare Professionals.
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January= 31, 2018.
CDC, AAP, and AAFP Update and Post Their 14 Childhood-immunization "Basic" = Disease Fact Sheets in English and Spanish CDC, the American Academy of Pediatrics, and the American Academy of Family= Physicians have updated their childhood-immunization =E2=80=9Cbasic=E2=80= =9D disease fact sheets http://messaging.aphanet.org/c/11truwBTLT6ovZgat16yKDwBliu in English and S= panish, and they are now available on CDC=E2=80=99s website.
Each of the 14 fact sheets provides an overview of a vaccine-preventable di= sease and related vaccine information. These fact sheets were co-developed = by CDC, AAP and AAFP for use with parents of children 0=E2=80=932 years old= . They are part of the Provider Resources for Vaccine Conversations with Pa= rents http://messaging.aphanet.org/c/11truEoCqIgTtqjICaEDh2iTGdH web section, whi= ch also includes communication guidance and vaccine safety resources. The f= act sheets can be viewed online as HTML pages or printed for distribution i= n clinicians' offices and at community health events.
There are updated fact sheets on the following diseases:
Chickenpox http://messaging.aphanet.org/c/11truMbl5xroqRngLkcHNr5c18U Diphtheria http://messaging.aphanet.org/c/11trv1KMpbMolJun3DiQQeDMGZk Hepatitis A http://messaging.aphanet.org/c/11trv9xv40WTjaxVcMQVmDq51Ux Hepatitis B http://messaging.aphanet.org/c/11trvhkdIQ7ogBBtlWoZT2cnmPK Hib http://messaging.aphanet.org/c/11trvp6WnFhTe2F1v5X4pqYFHKX Influenza (flu) http://messaging.aphanet.org/c/11trvwTF2usobtIzEfv8VPKY2Ga Measles http://messaging.aphanet.org/c/11trvEGnHjCT8UM7Np3dsexgnBn Mumps http://messaging.aphanet.org/c/11trvMt6m8No6lPFWyBhYDjyIwA Pneumococcal disease http://messaging.aphanet.org/c/11trvUfP0XXT3MTe5I9mv25R3rN Polio http://messaging.aphanet.org/c/11trw22xFN8o1dWMeRHr1qS9on0 Rotavirus http://messaging.aphanet.org/c/11trw9PgkCiSYF0ko1fvxPErJid Rubella http://messaging.aphanet.org/c/11trwpoHEgDSTx7qGklEADd2p8D Tetanus http://messaging.aphanet.org/c/11trwxbqj5OnQYaYPtTJ71ZkK3Q Whooping Cough (pertussis) http://messaging.aphanet.org/c/11trwEY8XUYSOpewYDrNDqLD4Z3
CDC will be retiring their in-depth disease fact sheets this spring.
Any questions can be sent to CDC by emailing childhoodvaccines-at-cdc.gov http://messaging.aphanet.org/c/11trwMKRCK9nLQi57MZS9PxVpUg.
Related Link
CDC's Provider Resources for Vaccine Conversations with Parents http://messaging.aphanet.org/c/11trwUxAhzjSJhlDgWxWGekdKPt web section
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January= 24, 2018.
IAC's Recently Updated Its Clinic Tools: Administering Vaccines Web Page, t= he "Go-to" Place for Accessing a Wide Variety of Valuable Resources IAC's Clinic Tools: Administering Vaccines http://messaging.aphanet.org/c/11trx2kiWounGIpbq661cD6w5KG web page on immu= nize.org is the "go-to" place for resources on vaccine administration. Upda= ted this month, this web page makes it easy to find a wide variety of educa= tional materials, resources, and tools related to vaccine administration fr= om IAC and from IAC partner organizations. This web page can be found by se= lecting the "Clinic Tools" tab (third from the left) in the light gray bann= er across the top of every immunize.org web page and then selecting "Admini= stering Vaccines" in the drop-down menu.
In the left-hand column of the page you will find IAC's educational materia= ls related to vaccine administration. From here, you can access handouts an= d standing orders as well as links to other related resources available on = immunize.org.
The right-hand column of the page includes resources from CDC and other par= tner organizations. For example, the second resource listed under CDC, the = Vaccination Administration Resource Library, http://messaging.aphanet.org/c/11trxa71BdESE9sJzfE5J1SOqFT brings readers d= irectly to the web page with CDC's e-Learn 18 vaccine administration video = clips. These video clips, ranging from around three to nine minutes in leng= th, have been excerpted for quick access from the e-Learn course. In this c= olumn, additional vaccine administration educational resources can be acces= sed from other IAC partners as well, including the Alliance for Immunizatio= n in Michigan, California Department of Public Health's EZ-IZ website, and = the American Academy of Pediatrics.
Visit the Clinic Tools: Administering Vaccines http://messaging.aphanet.org/c/11trxhTKg2PnBAwhIpcafqF6LB6 web page on immu= nize.org.
Related Link
View all IAC vaccine administration educational materials. http://messaging.aphanet.org/c/11trxpGsURZSz1zPRyKeLPrp6wj
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January= 24, 2018.
Influenza is Spreading and Serious; Please Keep Vaccinating Your Patients According to CDC, during the week of January 7=E2=80=9313, 2018, influenza = activity increased in the United States. The geographic spread of influenza= in Puerto Rico and 49 states was reported as widespread; Guam reported reg= ional activity; the District of Columbia and one state reported local activ= ity; and the U.S. Virgin Islands reported sporadic activity. Ten influenza-= associated pediatric deaths were reported.
Influenza vaccination is recommended for everyone six months of age and old= er. If you don't provide influenza vaccination in your clinic, please recom= mend vaccination to your patients and refer them to a clinic or pharmacy th= at provides vaccines or to the HealthMap Vaccine Finder http://messaging.aphanet.org/c/11trxxtbzHanwsDo0IijiedHrrw to locate sites = near their workplaces or homes that offer influenza vaccination services.
Following is a list of resources related to influenza disease and vaccinati= on for healthcare professionals and the public:
CDC's Seasonal Flu web section http://messaging.aphanet.org/c/11trxN2CTlvnrkKuj1osl1Mi7hW CDC's FluView web section http://messaging.aphanet.org/c/11trxUPlyaFSoLO2saWwRqyAsd9 CDC's Free Resources related to influenza http://messaging.aphanet.org/c/11try2C4cZQnmcRABkuBnPkSN8m IAC's handouts related to influenza http://messaging.aphanet.org/c/11tryaoMRP0SjDV8Ku2FUe7b83z HealthMap Vaccine Finder http://messaging.aphanet.org/c/11tryibvwEbnh4YGTDAKqCTtsYM National Adult and Influenza Immunization Summit http://messaging.aphanet.org/c/11trypYebtlSew2f2N8OX1FLNTZ website The Summit Buzz http://messaging.aphanet.org/c/11tryxKWQiwnbX5NbWGTtqs48Pc Newsletter of th= e National Adult and Influenza Immunization Summit Influenza Vaccine Availability Tracking System=E2=80=94IVATS http://messaging.aphanet.org/c/11tryFxFv7GS9o9ll6eXZPemtKp a resource for h= ealthcare settings looking to purchase influenza vaccine
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January= 24, 2018.
Healthcare Ready Releases issue brief entitled Pharmacy and Emergency Prepa= redness
Healthcare Ready has released an issue brief entitled Pharmacy and Emergenc= y Preparedness http://messaging.aphanet.org/c/11tryNko9WRn6PcTufN2we0EOFC. The issue brief= and a shorter snapshot are attached here. As a component of Resilient and = Ready: Healthcare=E2=80=99s Impact in Emergency Preparedness http://messaging.aphanet.org/c/11tryV76OM1S4ggrDpl72CMX9AP, Healthcare Read= y=E2=80=99s report examining trends in healthcare that are enhancing the pr= eparedness posture of the healthcare sector, this brief highlights advancem= ents in the field and novel resources available to pharmacy stakeholders wh= ile also summarizing emerging challenges.
As last year=E2=80=99s hurricane season and this year=E2=80=99s flu season = continue to underscore, pharmacies and pharmacists are absolutely indispens= able components of the healthcare system. This report showcases their effor= ts and capabilities through this effort.
Be FLUent =E2=80=93 Talk to Your 65+ Patients About Flu Prevention
http://messaging.aphanet.org/c/11trzaGy8qmRZ8nxVIrg5qlxPrf a pharmacist you= are on the front lines of patient care, and you can play a key role in eng= aging and informing your older patients about the dangers of flu, as well a= s the latest strategies for prevention. Be FLUent http://messaging.aphanet.org/c/11trzitgNfxmWzr64RZkBP7Qams offers a series = of tools and resources to help you lead the way in protecting adults age 65= years and older from flu.
Back to top
Education
National AHEC Organization to Sponsor February 15 Webinar Titled "How HPV C= auses Cancer and Why it Still Matters" The National AHEC Organization is sponsoring a webinar titled "How HPV Caus= es Cancer and Why it Still Matters" on February 15 at 3:00 p.m. (ET). Peter= C. Angeletti, associate professor, University of Nebraska=E2=80=93Lincoln,= Nebraska Center for Virology, School of Biological Sciences, will explain = the biology of HPV infection and the mechanism by which HPV causes cancer, = and then show evidence of different manifestations of HPV-related dysplasia= . He will also discuss the rationale for adopting an effective public HPV v= accination strategy and provide evidence for efficacy of the current vaccin= e.
Registration information http://messaging.aphanet.org/c/11trzqfZs4HRU0uEe1xp8dU8vhF
Source: Immunization Action Coalition. IAC Express. Issue No. 1347. January= 31, 2018.
Immunize Nevada Sponsors All-day Adult Immunization Summit Webinar on Febru= ary 16 Immunize Nevada is sponsoring an all-day Adult Immunization Summit webinar http://messaging.aphanet.org/c/11trzy2I6TSmRrycnb5tECGqQcS on February 16 f= rom 9:00=E2=80=932:30 p.m. Pacific Time (12:00=E2=80=935:30 p.m. ET). This = webinar is part of their NILE (Nevada Immunization Learning Exchange) webin= ar series. The day-long webinar will include four consecutive sessions; reg= ister individually for each one.
The titles of the four sessions are:
Pharmacists' Role within the Immunization Neighborhood Adult Immunizations Pneumococcal Vaccines for Adults Nevada Web IZ: Adult Immunization Improvement Project
Register on the Immunize Nevada http://messaging.aphanet.org/c/11trzFPqLJ2ROSBKwkDyb1sJb85 http://messaging.aphanet.org/c/11trzNC9qydmMjFiFubCHqf1w3i Webinars http://messaging.aphanet.org/c/11trzVoS5nnRJKIQODJHdP1jQYv web page.
Related Link
Immunize Nevada http://messaging.aphanet.org/c/11trA3bAKcymHbMoXNhLKdNCbTI
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January= 24, 2018.
NFID and mdBriefCase Group Inc. Offering On-demand CME Activity: "Seasonal = Influenza Immunization in the U.S.: Strategies for Protecting Older Adults" The National Foundation for Infectious Diseases (NFID) and mdBriefCase Grou= p Inc. are offering a free, online CME training titled "Seasonal Influenza = Immunization in the U.S.: Strategies for Protecting Older Adults." http://messaging.aphanet.org/c/11trAaYjp1IRECPX6WPQgCzUwOV This training ca= n be accessed on demand until February 18, 2018.
Upon completion of this activity, participants will be able to:
Describe the benefit of influenza vaccination in adults age 65 years and ol= der List the vaccine options available for seasonal influenza vaccination of ad= ults age 65 years and older Differentiate vaccine products approved for seasonal influenza in adults ag= e 65 years and older Effectively counsel older adult patients about the importance of seasonal i= nfluenza vaccination
View the information page for more details about this activity. http://messaging.aphanet.org/c/11trAiL23QTmC3Tvg6nUN1mcRK8 You can log on t= o the training at the bottom of the information page.
Source: Immunization Action Coalition. IAC Express. Issue No. 1341. Decembe= r 13, 2017.
CDC Has Rescheduled #PreteenVaxScene Webinar, =E2=80=9CAn Interprofessional= Approach to HPV and Oropharyngeal Cancer Prevention Education,=E2=80=9D fo= r February 21 http://messaging.aphanet.org/c/11trAyktnvemwW0Bypu3POUNxAy CDC has rescheduled its #PreteenVaxScene webinar, =E2=80=9CAn Interprofessi= onal Approach to HPV and Oropharyngeal Cancer Prevention Education,=E2=80= =9D for February 21, 2:00 p.m. (ET). This webinar had originally been sched= uled for January 8.
Register for the webinar. http://messaging.aphanet.org/c/11trAG7c2koRun49Hz28mdH5SvL
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January= 24, 2018.
Register Now for the Annual California Immunization Coalition Summit, April= 16=E2=80=9317 http://messaging.aphanet.org/c/11trANTUH9zmrO7HQIAcSCtodqY Register now for the 2018 California Immunization Coalition (CIC) Summit ti= tled "Onward and Upward," which will be held in Sacramento on April 16=E2= =80=9317. The CIC Summit web page http://messaging.aphanet.org/c/11trAVGDlYJRpfbfZS8hp1fGymb provides informa= tion and additional details, and it lists the following objectives for the = event:
provide support and technical assistance to enhance existing education, com= munication, and outreach efforts facilitate the sharing of successful strategies and best practices to stren= gthen local and statewide advocacy efforts encourage the adoption of programs for healthcare providers to promote and = deliver immunizations across the lifespan review new recommendations, issues and trends in immunizations and vaccine-= preventable diseases
View the draft agenda. http://messaging.aphanet.org/c/11trB3tm0NUmmGeO91GlVq1YTho
Register for the CIC Summit. http://messaging.aphanet.org/c/11trBbg4FD4Rk7imibeqrOOhecB
Related Link
California Immunization Coalition http://messaging.aphanet.org/c/11trBj2NksfmhylUrkMuYdAzz7O website
Source: Immunization Action Coalition. IAC Express. Issue No. 1346. January= 24, 2018.
NFID 2018 Annual Conference on Vaccinology Research to Be Held April 23=E2= =80=9325 in Bethesda The National Foundation for Infectious Diseases (NFID) is holding the 2018 = Annual Conference on Vaccinology Research (ACVR) on April 23=E2=80=9325 in = Bethesda, Maryland.
Related Links
2018 Annual Conference on Vaccinology Research website http://messaging.aphanet.org/c/11trBqPvZhpReZpsAukzuCmRU31 NFID's Online Education http://messaging.aphanet.org/c/11trByCeE6Amcqt0JDSE119aeYe web page
Source: Immunization Action Coalition. IAC Express. Issue No. 1341. Decembe= r 13, 2017.
Registration Now Open for CDC=E2=80=99s 48th National Immunization Conferen= ce on May 15=E2=80=9317, 2018 Registration is now open for the 48th National Immunization Conference (NIC= ), scheduled for May 15=E2=80=9317 http://messaging.aphanet.org/c/11trBGoXiVKR9RwySNqIxpVszTr at the Hilton Ho= tel in Atlanta. http://messaging.aphanet.org/c/11trBVYoCA5R4JDFb6wRAdu3fJR brings together = more than 1,500 local, state, federal, and private-sector immunization stak= eholders and partners to explore science, policy, education, and planning i= ssues related to immunization and vaccine-preventable diseases.
The NIC mission is to offer information that will help participants provide= comprehensive immunization services for all age groups. The conference als= o offers participants an opportunity to learn innovative strategies for dev= eloping programs and policies, and for advancing science to promote immuniz= ation among all ages today for a healthy tomorrow.
This three-day conference will include the following session tracks:
Adult Immunization Immunization Information Systems Programmatic Issues Health and Risk Communications Epidemiology and Surveillance Childhood/Adolescent Immunization
Access the National Immunization Conference (NIC) web page http://messaging.aphanet.org/c/11trC3L7hpgm2aHdkg4W6CglAF4, which includes = information about conference and hotel registration, fees, abstract submiss= ion, and more
Source: Immunization Action Coalition. IAC Express. Issue No. 1330. October= 11, 2017.
Registration is Open for the Epidemiology & Prevention of Vaccine-Preventab= le Diseases ("The Pink Book") Course in Colorado, September 11=E2=80=93=C2= =AD13 CDC faculty from its National Center for Immunization and Respiratory Disea= ses will present a comprehensive review of immunization principles and reco= mmendations for vaccines for vaccine-preventable diseases in a 2.5-day Epid= emiology and Prevention of Vaccine Preventable Diseases (The Pink Book) cou= rse. http://messaging.aphanet.org/c/11trCbxPWeqQZBKLtpD0D12DVAh by the Colorado = Children's Immunization Coalition and the Colorado Department of Public Hea= lth and Environment Immunization Branch, the course will take place in Gree= nwood Village, Colorado, on September 11=E2=80=9313.
View the course web page http://messaging.aphanet.org/c/11trCjkyB3BlX2OjCzb59pOWgvu the Colorado Chi= ldren's Immunization Coalition website. View the course's draft agenda and details regarding CE credits available http://messaging.aphanet.org/c/11trCr7hfSLQUtRRLIJ9FOBeBqH. View registration information and register for the course. http://messaging.aphanet.org/c/11trCyTZUHWlRUVpUShecdnwWlU
Source: Immunization Action Coalition. IAC Express. Issue No. 1344. January= 10, 2018.
Back to top
In This Issue
> News > Resources > Education
Follow Us: Facebook http://messaging.aphanet.org/c/11trCGGIzx6QPlYY41PiIC9Phh7 Twitter http://messaging.aphanet.org/c/11trCOtremhlMN2wdbnnf0W7Cck RSS http://messaging.aphanet.org/c/11trCWg9TbrQKe64mkVrLpIpX7x
http://messaging.aphanet.org/c/11trD42Sy0ClHF9CvutwhOuIi2K
Acknowledgements: APhA appreciates the time and expertise of these individu= als in creating the Immunizing Pharmacist News: Mitchel C. Rothholz, RPh, M= BA, managing editor; LuGina Mendez-Harper, PharmD, medical writer.
----17C5E3F746EDDA92B065881187F6 Content-Type: text/html; charset="UTF-8" Content-Transfer-Encoding: quoted-printable
dth=3D"620">
|
|
|
|
om/emailimages/Banners/Immunizing_Pharmacists-header.png" border=3D"0" alt= =3D"Immunizing Pharmacist"> |
|
|
size: 12px; padding: 20px; color: #616f7d; text-align: left;" width=3D"360"= valign=3D"top">
rnet/ems_templates/images/template2-div1.gif" alt=3D"" width=3D"345" height= =3D"5"> color: #3f92d2;">News
: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; = font-family: 'Segoe UI', 'Segoe UI Web', Arial, Verdana, sans-serif; font-s= ize: 12px;"> g: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-c= olor: transparent; overflow: visible; cursor: text; clear: both; position: = relative; direction: ltr; z-index: 0;"> Widespread Influenza Has Killed 37 Children; CDC Provides Related Med= ia Advisory CDC has reported in its g.aphanet.org/c/11tqKjqPsaMDJobu8kRIryRL9Jk" target=3D"_blank">Weekly U.S. = Influenza Surveillance Report, FluView, that as of the week ending Janu= ary 20, influenza has caused nearly 12,000 hospitalizations and 37 ped= iatric deaths since October 1, 2017. Because it takes time for deaths = outside of a hospital to be investigated, the reported number of pedia= tric deaths is likely to be an underestimate. The geographic sprea= d of influenza in Puerto Rico and 49 states was reported as widespread; Gua= m reported regional activity; the District of Columbia and one state report= ed local activity; and the U.S. Virgin Islands reported sporadic activity.<= br> On January 26, CDC held an update for the media titled "CDC U= pdate on Flu Activity." Part of the introductory statement from Dan Je= rnigan, MD, MPH, director, Influenza Division, National Center for Immuniza= tion and Respiratory Diseases, CDC, is reprinted below. It= has been a tough flu season so far, this year. And while flu activity is b= eginning to go down in parts of the country, it remains high for most the U= .S., with some areas still rising. Most people with influenza are being inf= ected with the H3N2 influenza virus. And in seasons where H3N2 is the main = cause of influenza, we see more cases, more visits to the doctor, more hosp= italizations, and more deaths, especially among older people. This season n= ow looking like the 2014–15 season where H3N2 predominated. ... We&rs= quo;ve experienced two notable characteristics of flu this season: The firs= t is that flu activity became widespread within almost all states and juris= dictions at the same time. The second is that flu activity has now stayed a= t the same level for 3 weeks in a row, with 49 states reporting widespread = activity, each week, for 3 weeks. We often see different parts of the count= ry “light up” at different times, but for the past 3 weeks, the= entire country has been experiencing lots of flu, all at the same time.&nb= sp; Access the 11tqKrdy6ZX8GPf2hupMXXE3uEx" target=3D"_blank">complete transcript or audio= recording from this media advisory. Influenza vaccinatio= n is recommended for everyone six months of age and older. If you don't pro= vide influenza vaccination in your clinic, please recommend vaccination to = your patients and refer them to a clinic or pharmacy that provides vaccines= or to the DXRumqlPzK" target=3D"_blank">HealthMap Vaccine Finder to locate s= ites near their workplaces or homes that offer influenza vaccination servic= es. Following is a list of resources related to influenza disease = and vaccination for healthcare professionals and the public: Source: Immunization Action Coalition. IAC Express. Issue No= . 1347. January 31, 2018.
CDC Publishes ACIP Recommendations for Use of Herpes Zoster Vaccines = in MMWR CDC published saging.aphanet.org/c/11tqLORtm4ODeCS5UbsAImdjcNQ" target=3D"_blank">Recomme= ndations of the Advisory Committee on Immunization Practices for Use of Her= pes Zoster Vaccines in the January 26 issue of MMWR&nb= sp;(pages 103–8). The "Introduction" and "Clinical Guidance" sections= are reprinted below: Introduction On Octo= ber 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, Glax= oSmithKline), a 2-dose, subunit vaccine containing recombinant glyco= protein E in combination with a novel adjuvant (AS01B), was approved by the= Food and Drug Administration for the prevention of herpes zoster in adults= aged ≥50 years. The vaccine consists of 2 doses (0.5 mL each), admin= istered intramuscularly, 2–6 months apart. On October 25, 2017, t= he Advisory Committee on Immunization Practices (ACIP) recommended the reco= mbinant zoster vaccine (RZV) for use in immunocompetent adults aged ≥= 50 years. Herpes zoster is a localized, usually painful= , cutaneous eruption resulting from reactivation of latent varicella zoster= virus (VZV). Herpes zoster is common: approximately one million cases occu= r each year in the United States. The incidence increases with age, from fi= ve cases per 1,000 population in adults aged 50–59 years to 11 cases = per 1,000 population in persons aged ≥80 years. Postherpetic neuralgia, = commonly defined as persistent pain for at least 90 days following the reso= lution of the herpes zoster rash, is the most common complication and occur= s in 10%–13% of herpes zoster cases in persons aged >50 years. Amo= ng persons with herpes zoster, the risk for developing postherpetic neuralg= ia also increases with age. Zoster Vaccine Live (ZVL= ) (Zostavax, Merck and Co., Inc.), a 1-dose live attenuated s= train of VZV, is licensed for the prevention of herpes zoster in immuno= competent adults aged ≥50 years and is recommended by the ACIP for us= e in immunocompetent adults aged ≥60 years. Since licensure, vaccine= coverage has increased each year, and by 2016, 33% of adults aged ≥60 y= ears reported receipt of the vaccine (CDC, provisional unpublished data). A= CIP considered use of RZV, as well as existing recommendations, to develop = vaccination policy which would be safe and reduce disease burden. This repo= rt serves as a supplement to the 2008 Prevention of Herpes Zoster Recommend= ations of ACIP for the use of ZVL in adults aged ≥60 years and subsequen= t updates; it outlines recent ACIP recommendations as well as guidance for = use of RZV and ZVL in adults. Clinical Guidance = General use. RZV may be used in adults aged ≥50 years, irrespe= ctive of prior receipt of varicella vaccine or ZVL, and does not require sc= reening for a history of chickenpox (varicella). ZVL remains a recommended = vaccine for prevention of herpes zoster in immunocompetent adults aged ≥= 60 years. Care should be taken not to confuse ZVL, which is stored in th= e freezer and administered subcutaneously, with RZV, which is stored in the= refrigerator and administered intramuscularly. Dosing = schedule. Following the first dose of RZV, the second dose shou= ld be given 2–6 months later. The vaccine series need not be restarte= d if more than 6 months have elapsed since the first dose; however, the eff= icacy of alternative dosing regimens has not been evaluated, data regarding= the safety of alternative regimens are limited, and individuals might rema= in at risk for herpes zoster during a longer than recommended interval betw= een doses 1 and 2. If the second dose of RZV is given less than 4 weeks aft= er the first, the second dose should be repeated. Two doses of the vaccine = are necessary regardless of prior history of herpes zoster or prior receipt= of ZVL. Timing of RZV for persons previously vaccinated wi= th ZVL. Age and time since receipt of ZVL may be considered to deter= mine when to vaccinate with RZV. Studies examined the safety and immunogeni= city of RZV vaccination administered ≥5 years after ZVL; shorter interva= ls have not been studied. However, there are no data or theoretical concern= s to indicate that RZV would be less safe or less effective when administer= ed at an interval of <5 years. Clinical trials indicated lower efficacy = of ZVL in adults aged ≥70 years; therefore, a shorter interval may be co= nsidered based on the recipient’s age when ZVL was administered. Base= d on expert opinion, RZV should not be given <2 months after receipt of = ZVL. Coadministration with other vaccines. CDC&= rsquo;s general best practice guidelines for immunization advise that recom= binant and adjuvanted vaccines, such as RZV, can be administered concomitan= tly, at different anatomic sites, with other adult vaccines. Concomitant ad= ministration of RZV with Fluarix Quadrivalent (influenza vaccine) (QIV) has= been studied, and there was no evidence for interference in the immune res= ponse to either vaccine or safety concerns. Evaluation of coadministration = of RZV with 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumova= x23) and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis= vaccine, adsorbed (Tdap, Boostrix) is ongoing. The safety and efficacy of = administration of two adjuvanted vaccines (e.g., RZV and adjuvanted influen= za vaccine [Fluad]), either concomitantly or at other intervals, have not b= een evaluated. Counseling for reactogenicity. B= efore vaccination, providers should counsel RZV recipients about expected s= ystemic and local reactogenicity. Reactions to the first dose did not stron= gly predict reactions to the second dose; vaccine recipients should be enco= uraged to complete the series even if they experienced a grade 1–3 re= action to the first dose of RZV. The impact of prophylactic analgesics in c= onjunction with RZV has not been studied. Access the compl= ete recommendation: 0TZ8c3VE3l0FeKZBxJ3" target=3D"_blank">Recommendations of the Advisory Comm= ittee on Immunization Practices for Use of Herpes Zoster Vaccines. =
Source: Immunization Action Coalition. IAC Express. Issue No. 1= 347. January 31, 2018. arget=3D"_self">Draft Agenda for February ACIP Meeting Available=
ACIP will hold its next meeting on February 21–22 in Atlanta. Th= e draft agenda is now available online. To attend the meeting, ACIP at= tendees (participants and visitors) must register online. The registration = deadline for non-U.S. citizens is January 24; for U.S. citizens, it's Febru= ary 5. Registration is not required to watch the meeting via webcast or lis= ten to the proceedings via phone. See the first link below for the toll-fre= e phone number and passcode. Related Links |
|
 |
|
|
 |
 |
|
|
|